
				Agenda Ov	erview Day 1			
Opening Keynotes				Opening Keynotes		Opening Keynotes		
				Mornir	ng Break			
Plenary Roundtable Session				Plenary Roundtable		Plenary Roundtable Session		
	Speed N	etworking		Speed Networking		Speed Networking		
		Di						
AI	МР	Вюрі	rocess	Cord Blood		Precision Medicine		
 The Cell & Gene C-level Forum Regulation & reimbursement, & market access Investment & funding strategies Clinical development & product release 	Clinical Development of ATMPS Clinical development of Immunotherapy & cell therapy Advances in autologous cell therapy (CAR-T cells, NK Cells, DCs, iPSCs & MSCs)	 Process Development & Manufacturing – Gene Therapy New paradigms in manufacture: gene therapy and viral vectors Maintaining cold chain and logistics for gene therapy and viral vectors 	 Continuous manufacturing: drivers and critical enablers Automated manufacture of biologics Accelerated CMC & process development Media development 	 Cord Blood Innovative applications of cord blood Collection, bioprocessing & storage Expansion & engraftment 	 Diagnostics Whole genome sequencing Liquid biopsy development and use Biomarker discovery and host biomarker approach 	 Big data and genomics Data security and sharing Information handling Big health data access Real world case studies and instights Integrating clinical and genomic information 	Infrastructure investment Investment in private partne Investment in medicine Accelerating medicine hea Collaboration Collabs betwe pharma/biote	arough pub erships nto precision precision alth ons veen innov
				Afternoon Refreshments				
Plenary Keynote				Plenary Keynote Plenary Keynote				
				Offsite Netw	orking Drinks			
			Agenda Overview Day 2					
Opening Keynotes					Opening Keynotes Opening Keynotes		Keynotes	
					ng Break			
АТМР			Bioprocess Cord Blood		Precision Medicine			
The Cell & Gene C-level Forum • Regulation, Reimbursement & Commercialisation of Advanced Therapies around the Globe	Clinical Development of ATMPS Immuno-oncology and cell therapy focus Moving from phase II to phase III	Future of Regen Med and Organ Regeneration • Starting materials, isolation & selection of target cells, cell culture, activation and stimulation • Stem cells as a research tool • Stem cell transplantations • Tissue engineering and organ regeneration	 Process Development & Manufacturing – Gene Therapy Process development: Scale up and scale out GMP Manufacturing & formulation of finished product Non-clinical development programmes 	Downstream Bioprocessing • Continuous manufacture • Single-use • Media development • Gene editing and CRIPR	 Cord Blood Public & private cord blood banking Regulation Banking other tissue 	Plenary Roundtable Session Speed Networking Patient involvement in precision me What are the benefits of involving the pub The patient experience with precision med involvement How clinicians can improve the patient ex What are the barriers to involvement and ho		ecision me d patient e
				Lu	inch			
АТМР			Bioprocess		Cord Blood	Precision Medicine		
The Cell & Gene C-level Forum • Regulatory updates	Biotech showcases Exciting academic spinouts and biotechs from around the world	 Future of Regen Med and Organ Regeneration Starting materials, isolation & selection of target cells, cell culture, activation and stimulation Stem cells as a research tool Stem cell transplantations Tissue engineering and organ regeneration 	 Process Development & Manufacturing Process development: Scale up and scale out GMP Manufacturing & formulation of finished product Non-clinical development programmes 	Supply Chain Management Cryopreservation & labelling Cell banking & repositories Logistics, Transport & Shipping	 Cord Blood Successes & challenges- from lab to clinic Cord blood transplant case studies Haploidentical vs cord blood transplants 	 Drug development Precision medicine approach to drug development across therapeutic areas Pharmacogenetics for drug development Genomic scale drug design 	 Precision met therapeutic of A look at dew precision met therapeutics therapy areas Oncology Rare disease Other therape 	developing edicine across va s
Plenary Keynote				Afternoon Refreshments				
				Poster Zone and	Plenary Keynote Networking Drinks	Plenary Keynote		
					erview Day 3			
		ATMD					Dresision	
ATMP					Precision Medic			
 Gene editing, CRISPR, cell line development and using stem cells and a tool for drug discovery Gene editing, CRISPR, and cell line development as a tool for stem cell discovery Using IPSCs as a disease model in drug-discovery Characterisation and imaging assays Identifying drug targets and mechanisms Establishing technology platforms and assays that balance throughput and biological relevance 					Beyond the genome Precis • Using proteomics, metabolomics, transcriptomics and the microbiome for precision medicine • A loc • Whole body screening • Integrated platforms • Multi-omics • Other			



icine

sision medicine therapeutic development

ook at developing precision medicine therapeutics across various therapy areas acology re disease

her therapeutic areas